Jacobs Levy Equity Management
PDSB icon

Jacobs Levy Equity Management’s PDS Biotechnology PDSB Stock Holding History

Jacobs Levy Equity Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-57,651
Closed -$171K – 1016
2022
Q3 		$171K Buy
+57,651
New +$245K ﹤0.01% 944
2017
Q2 		– Sell
-1,985
Closed -$362K – 993
2017
Q1 		$362K Buy
+1,985
New +$393K 0.01% 698

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's PDSB Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of PDS Biotechnology (PDSB) in Q4 2022, closing a stake of 57,651 shares — an estimated $171K sold.

Jacobs Levy Equity Management first reported a position in PDSB in Q1 2017 and held it in 2 quarters. The position peaked at $362K in Q1 2017. 64 funds tracked by Wall St. Rank hold PDSB as of Q4 2022.

  • Jacobs Levy Equity Management reported no remaining PDS Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 57,651 PDS Biotechnology shares in Q4 2022, an estimated $171K.
  • Jacobs Levy Equity Management first reported a position in PDS Biotechnology in Q1 2017 and held it in 2 quarters.
  • Jacobs Levy Equity Management's PDS Biotechnology position peaked at $362K in Q1 2017.
  • 64 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.